2642224-15-3
Chemical Structure
TAS1440 benzoate
- CAS No.: 2642224-15-3
- Formula:C35H33F2N3O4
- Molecular Weight:597.65
InChIKey: KFILLKGZKWCPOS-BOXHHOBZSA-N
SMILES: O=C(O)C1=CC=CC=C1.N[C@H](C2)CCN2C(C(C=C3C4=CC=C(C#N)C(F)=C4)=CC=C3C5=CC=C(C=C5F)CC(C)(C)O)=O
Biological Activity: TAS1440 benzoate is an orally active LSD1/KDM1A inhibitor with a human IC50 of 4.8 nM. TAS1440 benzoate non-covalently binds to the histone H3-binding pocket of LSD1, inhibiting demethylase activity and disrupting repressive complexes with INSM1 and SMAD2. TAS1440 benzoate activates tumor-suppressive TGF-β and NOTCH signaling pathways via transcriptional reprogramming. TAS1440 benzoate can be used for the research of small cell lung cancer, specifically the SCLC-A subtype[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
TAS1440 benzoate | TAS1440 benzoate is an orally active LSD1/KDM1A inhibitor with a human IC50 of 4.8 nM. TAS1440 benzoate non-covalently binds to the histone H3-binding pocket of LSD1, inhibiting demethylase activity and disrupting repressive complexes with INSM1 and SMAD2. TAS1440 benzoate activates tumor-suppressive TGF-β and NOTCH signaling pathways via transcriptional reprogramming. TAS1440 benzoate can be used for the research of small cell lung cancer, specifically the SCLC-A subtype. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
